Xellia Pharmaceuticals, a specialty pharmaceutical company focused on anti-infectives, has expanded its product and innovation research and development (R&D) team with more than 15 scientists and has added approximately 1,000 square meters of new space at its Center of Excellence in Zagreb, Croatia.

Xellia’s portfolio includes both difficult-to-develop-and-manufacture fermentation-based active pharmaceutical ingredients as well as sterile finished dosage forms.

Part of the work of the Zagreb facility will be to develop new chemical entities effective against antimicrobial resistance.

The recent expansion in Croatia increases the company’s total investment in R&D activities there to more than HRK 200 million ($30 million) since the center was established in 2011.

Source: Xellia Pharmaceuticals